Archivum Immunologiae et Therapiae Experimentalis

Papers
(The TQCC of Archivum Immunologiae et Therapiae Experimentalis is 11. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Long-Term Biodistribution and Safety of Human Dystrophin Expressing Chimeric Cell Therapy After Systemic-Intraosseous Administration to Duchenne Muscular Dystrophy Model33
The Effects of Statins on Respiratory Symptoms and Pulmonary Fibrosis in COVID-19 Patients with Diabetes Mellitus: A Longitudinal Multicenter Study33
Updated Clinical Perspectives and Challenges of Chimeric Antigen Receptor-T Cell Therapy in Colorectal Cancer and Invasive Breast Cancer32
Immunology and Donor-Specific Antibodies in Corneal Transplantation31
Antioxidant and Anti-inflammatory Effects of α-Lipoic Acid on Lipopolysaccharide-induced Oxidative Stress in Rat Kidney29
The Role of Non-essential Amino Acids in T Cell Function and Anti-tumour Immunity29
Should Nano-Particles be Weighed or Counted? Technical Considerations to In Vitro Testing Originated from Corpuscular Nature of Nano-Particles26
Correction to: In Situ Programming of CAR-T Cells: A Pressing Need in Modern Immunotherapy21
Sex Differences in Innate Immune Response of Peripheral Blood Leukocytes of Alzheimer’s Disease Patients20
Small Extracellular Vesicles Loaded with Immunosuppressive miRNAs Leads to an Inhibition of Dendritic Cell Maturation20
What Has Immunology Brought to Periodontal Disease in Recent Years?17
Mast Cells and Resistance to Immunotherapy in Cancer17
Elevated Levels of Soluble CD147 are Associated with Hyperinflammation and Disease Severity in COVID-19: A Proof-of-Concept Clinical Study13
Chronic Prostatitis and Pelvic Pain Syndrome: Another Autoimmune Disease?13
Peroxiredoxins as Markers of Oxidative Stress in IgA Nephropathy, Membranous Nephropathy and Lupus Nephritis13
Assessment of Motor Unit Potentials Duration as the Biomarker of DT-DEC01 Cell Therapy Efficacy in Duchenne Muscular Dystrophy Patients up to 12 Months After Systemic–Intraosseous Administration12
Application of Metabolomics in Childhood Leukemia Diagnostics12
Molecular Genetics Diversity of Primary Hemophagocytic Lymphohistiocytosis among Polish Pediatric Patients11
0.19517016410828